Lv11
50 积分 2025-07-25 加入
Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC
2小时前
待确认
Breakthrough in RAS targeting with pan-RAS(ON) inhibitors RMC-7977 and RMC-6236
3个月前
已完结
Ocular toxicities of fibroblast growth factor receptor inhibitors: A review
4个月前
已完结
BL-B01D1, a first-in-class EGFR-HER3 bispecific antibody-drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study
5个月前
已完结
The Skin Picking Impact Scale: Factor structure, validity and development of a short version
5个月前
已完结
DRUG-ASSOCIATED PRIMARY ACUTE PANCREATITIS
6个月前
已完结
Drug-induced acute pancreatitis: Prevalence, Causative agents, and Outcomes
6个月前
已完结
Recommendations for the Use of White Blood Cell Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update
6个月前
已完结
Interstitial Lung Disease Induced by Anti-ERBB2 Antibody-Drug Conjugates
9个月前
已完结
Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial
1年前
已完结
皖公网安备34019202002308
